A phase I pharmacokinetic, pharmacogenomic trial of weekly amonafide in patients (pts) with solid tumors.

Abstract

2023 Background: Amonafide (AMF) is a topoisomerase II inhibitor previously tested in clinical trials, predominantly with a daily x 5 administration schedule. AMF is extensively metabolized by N-acetyltransferase 2 to N-acetylamonafide (AAMF), an active metabolite which demonstrates nearly equipotent activity to the parent compound. Previous trials… (More)

Topics

Cite this paper

@article{Kuhn2004API, title={A phase I pharmacokinetic, pharmacogenomic trial of weekly amonafide in patients (pts) with solid tumors.}, author={Jens Kuhn and Steven J. M. Jones and D. Hein and Noel T Willcutt and F Anthony Greco and Eric L Raefsky and Dominic Thompson and Anthony A Meluch and David A. Brown and Howard A. Burris}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2004}, volume={22 14_suppl}, pages={2023} }